Combination of erythropoietin and tranexamic acid in bilateral simultaneous total hip arthroplasty: A randomised, controlled trial

HIP International

Volumn 26, Issue 4, 2016, Pages 331-337

  Wu, Yuan Gang ^a   Zeng, Y ^a   Shen, Bin ^a   Si, Hai Bo ^a   Cao, Fei ^a   Yang, Ti Min ^a   Pei, Fu Xing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Erythropoietin; Simultaneous total hip arthroplasty; Tranexamic acid; Transfusion

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON POLYSACCHARIDE; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD DRAINAGE VOLUME; BLOOD TRANSFUSION; CALF MUSCULAR VEIN THROMBOSIS; CELLULITIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIZZINESS; DOPPLER FLOWMETRY; FATIGUE; FEMALE; HEADACHE; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HIP ARTHROPLASTY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPERATIVE BLOOD LOSS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; AGED; BLOOD; BLOOD CELL COUNT; COMBINATION DRUG THERAPY; FEMUR HEAD NECROSIS; HIP DISLOCATION; HIP REPLACEMENT; MEAN CORPUSCULAR VOLUME; OSTEOARTHRITIS, HIP;

ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; ARTHROPLASTY, REPLACEMENT, HIP; BLOOD CELL COUNT; BLOOD TRANSFUSION; DRUG THERAPY, COMBINATION; ERYTHROCYTE INDICES; ERYTHROPOIETIN; FEMALE; FEMUR HEAD NECROSIS; HIP DISLOCATION; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; PROSPECTIVE STUDIES; TRANEXAMIC ACID;

EID: 84979650016     PISSN: 11207000     EISSN: None     Source Type: Journal    
DOI: 10.5301/hipint.5000356     Document Type: Article

References (27)

1. Aghayev E, Beck A, Staub LP, et al. Simultaneous bilateral hip replacement reveals superior outcome and fewer complications than two-stage procedures: a prospective study including 1819 patients and 5801 follow-ups from a total joint replacement registry. BMC Musculoskelet Disord. 2010; 11(1):245.
2. Glait SA, Khatib ON, Bansal A, Hochfelder JP, Slover JD. Comparing the Incidence and Clinical Data for Simultaneous Bilateral Versus Unilateral Total Hip Arthroplasty in New York State Between 1990 and 2010. J Arthroplasty. 2015;30(11):1887-1891.
3. Romagnoli S, Zacchetti S, Perazzo P, Verde F, Banfi G, Viganò M. Simultaneous bilateral total hip arthroplasties do not lead to higher complication or allogeneic transfusion rates compared to unilateral procedures. Int Orthop. 2013;37(11): 2125-2130.
4. Henry DA, Carless PA, Moxey AJ, et al. Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2002;(2): CD003602.
5. Paul JE, Ling E, Lalonde C, Thabane L. Deliberate hypotension in orthopedic surgery reduces blood loss and transfusion requirements: a meta-analysis of randomized controlled trials. Can J Anaesth. 2007;54(10):799-810.
6. Bryson GL, Laupacis A, Wells GA; The International Study of Perioperative Transfusion. Does acute normovolemic hemodilution reduce perioperative allogeneic transfusion? A metaanalysis. Anesth Analg. 1998;86(1):9-15.
7. Hill SR, Carless PA, Henry DA, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2002;(2):CD002042.
8. Gondusky JS, Pinkos KA, Choi L, Patel JJ, Barnett S, Gorab RS. Simultaneous Bilateral Anterior Approach Total Hip Arthroplasty. Orthopedics. 2015;38(7):e611-e615.
9. Wei W, Wei B. Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty. J Arthroplasty. 2014;29(11):2113-2116.
10. Gillette BP, DeSimone LJ, Trousdale RT, Pagnano MW, Sierra RJ. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. Clin Orthop Relat Res. 2013;471(1):150-154.
11. Gombotz H, Gries M, Sipurzynski S, Fruhwald S, Rehak P. Preoperative treatment with recombinant human erythropoietin or predeposit of autologous blood in women undergoing primary hip replacement. Acta Anaesthesiol Scand. 2000;44(6): 737-742.
12. Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res. 2009;123(5): 687-696.
13. Alsaleh K, Alotaibi GS, Almodaimegh HS, Aleem AA, Kouroukis CT. The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty: a meta-analysis of randomized clinical trials. J Arthroplasty. 2013;28(9):1463-1472.
14. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med. 2000;133(11):845-854.
15. Cherian JJ, Kapadia BH, Issa K, et al. Preoperative blood management strategies for total hip arthroplasty. Surg Technol Int. 2013;23:261-266.
16. As-Sultany M, Pagkalos J, Yeganeh S, et al. Use of oral direct factor Xa inhibiting anticoagulants in elective hip and knee arthroplasty: a meta-analysis of efficacy and safety profiles compared with those of low-molecular-weight heparins. Curr Vasc Pharmacol. 2013;11(3):366-375.
17. Kwong LM. Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis. Orthopedics. 2012;35(6):e932-e938.
18. Barnes CL, Nelson CL, Nix ML, McCowan TC, Lavender RC, Barnes RW. Duplex scanning versus venography as a screening examination in total hip arthroplasty patients. Clin Orthop Relat Res. 1991;(271):180-189.
19. Gross JB. Estimating allowable blood loss: corrected for dilution. Anesthesiology. 1983;58(3):277-280.
20. Bhan S, Pankaj A, Malhotra R. One- or two-stage bilateral total hip arthroplasty: a prospective, randomised, controlled study in an Asian population. J Bone Joint Surg Br. 2006;88(3): 298-303.
21. Laffosse JM, Minville V, Chiron P, et al. Preoperative use of epoietin beta in total hip replacement: a prospective study. Arch Orthop Trauma Surg. 2010;130(1):41-45.
22. Ho KM, Ismail H. Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis. Anaesth Intensive Care. 2003; 31(5):529-537.
23. Anaissie EJ, Coleman EA, Goodwin JA, et al. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer. 2012;118(2):549-557.
24. Bedair H, Yang J, Dwyer MK, McCarthy JC. Preoperative erythropoietin alpha reduces postoperative transfusions in THA and TKA but may not be cost-effective. Clin Orthop Relat Res. 2015;473(2): 590-596.
25. Green WS, Toy P, Bozic KJ. Cost minimization analysis of preoperative erythropoietin vs autologous and allogeneic blood donation in total joint arthroplasty. J Arthroplasty. 2010; 25(1):93-96.
26. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int. 2003;64(1):295-304.
27. Naci H, de Lissovoy G, Hollenbeak C, et al. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis. J Med Econ. 2012;15(2): 293-304.